Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...
The incidence of neonatal herpes simplex virus (HSV) infections in the UK and Ireland increased dramatically over 15 years, and outcomes remained poor, with mortality and long-term neurologic ...
In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...
Herpes simplex virus partially liquefies the tightly packed, gel-like interior of human cell nuclei to copy itself faster, a new study shows. The research centers on how the nucleus of each human cell ...
Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020. (HealthDay News) — The incidence and prevalence of genital ...
The frequency of clinically evident genital infections with herpes simplex virus among students attending a large urban public university was studied. One-hundred ninety-eight students experienced 222 ...
Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7% of immunocompromised patients achieving lesion healing. The ...
Ongoing research aims to confirm the mechanism by which ICP4 fluidizes the nucleus, which could indicate specific targets to counter viral replication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results